EQS-News

Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico

EQS-News: Marinomed Biotech AG / Key word(s): Market Launch Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico 11.04.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico

• Launch of new allergen-blocking nasal spray in Austria for the treatment of hay fever complements existing OTC product portfolio
• Partner M8 Pharmaceuticals launches Carragelose nasal spray for the treatment of viral respiratory infections in Mexico
• Further value maximization and revenue potential for Carragelose asset

Korneuburg, Austria, 11 April 2024 – Marinomed Biotech AG (VSE:MARI) today announces the expansion of its Carragelose product portfolio with new launches in Austria and Mexico, paving the way for targeting new indications and access to key markets. A new nasal spray formulation for the treatment of the symptoms of hay fever caused by grass pollen allergy has been launched by Marinomed’s Austrian distribution partner Sigmapharm under the brand name COLDAMARIS Allergie. Offering both symptom prevention and relief of allergic symptoms such as dryness in the nasal cavity, runny or blocked nose, itching and sneezing, this market entry perfectly coincides with the peak of this year’s allergy season. The launch of the allergen-blocking nasal spray also represents an important landmark in the expansion of the established Carragelose portfolio from blocking viruses to allergic indications, providing year-round revenue generation beyond the typical cold season.

Furthermore, following the successful market approval of a Carragelose nasal spray in Mexico by its distribution partner M8 Pharmaceuticals (an Acino company) last summer, the product is now available under the brand name Barlo. Targeting the Mexican market, which is Latin America’s second largest pharmaceutical market, this launch represents a significant revenue potential.

“With the market launch of our first Carragelose product in the Immunology segment and the product launch in Mexico, the second largest pharmaceutical market in Latin America, we have set important milestones in the ongoing expansion of our Carragelose portfolio. We are well on our way to close further geographic gaps in Europe, the Middle East and Latin America with new and existing partners and are now also targeting new indications. This makes us less dependent on the cold season, enables year-round sales and lets us expect new growth opportunities”, Andreas Grassauer, CEO of Marinomed, comments. “In addition to these developments, the launch of the Carragelose-containing eye drops and the filing for approval with Procter & Gamble in the U.S. are making good progress as well.”